



# Photo-Induced Electron Transfer Real-Time PCR for Detection of *Plasmodium falciparum plasmepsin 2* Gene Copy Number

Samaly Santos Souza,<sup>a</sup> Mariangela L'Episcopia,<sup>b</sup> Carlo Severini,<sup>b</sup> Venkatachalam Udhayakumar,<sup>a</sup> Naomi W. Lucchi<sup>a</sup>

<sup>a</sup>Centers for Disease Control and Prevention, Center for Global Health, Division of Parasitic Diseases and Malaria, Atlanta, Georgia, USA

<sup>b</sup>Istituto Superiore di Sanità, Rome, Italy

**ABSTRACT** Piperavaquine is an important partner drug used in artemisinin-based combination therapies (ACTs). An increase in the *plasmepsin 2* and *3* gene copy numbers has been associated with decreased susceptibility of *Plasmodium falciparum* to piperavaquine in Cambodia. Here, we developed a photo-induced electron transfer real-time PCR (PET-PCR) assay to quantify the copy number of the *P. falciparum plasmepsin 2* gene (*PfPM2*) that can be used in countries where *P. falciparum* is endemic to enhance molecular surveillance.

**KEYWORDS** PET-PCR, piperavaquine, copy number, malaria

Malaria is one of the most common and serious tropical diseases in the world, with roughly 216 million cases and an estimated 445,000 malaria deaths globally (1). Malaria is caused by intracellular parasitic protozoa of the genus *Plasmodium*. *Plasmodium falciparum* is the most virulent among the human malarial parasites and causes disease with high morbidity and mortality (1, 2). The first-line therapy recommended by the World Health Organization for uncomplicated malaria caused by *P. falciparum* is artemisinin-based combination therapy (ACT) (4, 5), which consists of an artemisinin derivative combined with a partner drug of another class of antimalarial. However, resistance to artemisinin and partner drugs has been reported in Southeast Asia and confirmed by therapeutic efficacy studies (6–10). Dihydroartemisinin and piperavaquine combination therapy is considered one of the remaining effective therapies against *P. falciparum* malaria; however, with the recent emergence of resistance to piperavaquine, along with artemisinin in Southeast Asia, molecular surveillance to detect piperavaquine-resistant parasites is now of utmost importance (7, 11–14). Recently, an increase in the copy number of the *plasmepsin 2–3* gene cluster in *P. falciparum* (*PfPM2–3*) was demonstrated to be associated with piperavaquine resistance in Cambodia (11, 15, 16). This gene amplification was determined using genome-wide analysis of copy number variation and a singleplex TaqMan probe-based real-time-PCR (16). This real-time PCR method requires two separate singleplex PCRs (to amplify the single-copy housekeeping *P. falciparum*  $\beta$ -tubulin gene and the *PfPM2* gene of interest) and the use of a TaqMan probe or DNA intercalating dye. We previously demonstrated that the self-quenching photo-induced electron transfer (PET) fluorogenic primers used in the PET-PCR assay provide a more convenient to use and less expensive real-time PCR assay than conventional probe-based real-time PCR formats, as no internal probes (e.g., TaqMan probes) or intercalating dyes are required (17, 18). We designed and evaluated a multiplex PET-PCR assay (results obtained using a single PCR) to determine the number of copies of *PfPM2* gene in *P. falciparum*. This novel assay was compared with the previously published singleplex TaqMan probe-based real-time PCR assay (16).

The *PfPM2* and *P. falciparum*  $\beta$ -tubulin gene primers used in this study were previously reported by Witkowski and collaborators (16). In our multiplex PET-PCR

Received 26 February 2018 Returned for modification 5 April 2018 Accepted 30 May 2018

Accepted manuscript posted online 4 June 2018

**Citation** Souza SS, L'Episcopia M, Severini C, Udhayakumar V, Lucchi NW. 2018. Photo-induced electron transfer real-time PCR for detection of *Plasmodium falciparum plasmepsin 2* gene copy number. Antimicrob Agents Chemother 62:e00317-18. <https://doi.org/10.1128/AAC.00317-18>.

**Copyright** © 2018 American Society for Microbiology. All Rights Reserved.

Address correspondence to Samaly Santos Souza, [ynp4@cdc.gov](mailto:ynp4@cdc.gov), or Naomi W. Lucchi, [frd9@cdc.gov](mailto:frd9@cdc.gov).


**TABLE 1** Oligonucleotide primer sequences used in the PET-PCR *PfPM2* copy number assay<sup>a</sup>

PET-PCR primer	PET-PCR sequence (5' to 3')	$T_m$ (°C)	Product size (bp)	Melting temp range (°C)
PfPM2_F	TGGTGATGCAGAAGTTGGAG	59.8	79	76.8–77.2
PfPM2_R_FAM	<b>aggcgcatagcgctgg</b> TGGGACCCATAAATTAGCAGA	59.4		
Pf $\beta$ -tubulin_F	TGATGTGCGCAAGTGATCC	61.9	87	79.0–79.2
Pf $\beta$ -tubulin_R_HEX	<b>aggcgcatagcgctgg</b> TCCTTTGTGGACATTCTCCTC	60.5		

<sup>a</sup>The PET-tag (lowercase letters in bold) attached to the 5' end of the target-specific sequences does not show any homology to *Plasmodium* species. The *PfPM2* (gene accession no. PF3D7\_1408000-811659) and  $\beta$ -tubulin gene (gene accession no. PF3D7\_1008700) primers were previously reported in the singleplex probe-based real-time PCR assay (16).

assay, the reverse primers of both *PfPM2* and the *P. falciparum*  $\beta$ -tubulin gene were modified with the PET tag and labeled with 6-carboxyfluorescein (FAM; *PfPM2*) and HEX (*P. falciparum*  $\beta$ -tubulin gene) fluorophores, as previously described by Lucchi et al. (17) (Table 1). The PET-PCR was carried out in a 20- $\mu$ l volume containing 2 $\times$  TaqMan Environmental master mix 2.0 (Applied Biosystems, Foster City, CA, USA), 0.5  $\mu$ M each forward and reverse primer for *PfPM2*, 0.25  $\mu$ M for the *P. falciparum*  $\beta$ -tubulin gene primers, and 3  $\mu$ l of template DNA. The amplifications were performed under the following conditions: 95°C for 15 min, 45 cycles of 95°C for 15 s, 58°C for 1 min, and 72°C for 20 s. All samples were tested in triplicate, and the assays were performed using Agilent Mx3005pro thermocyclers (Agilent Technologies, Santa Clara, CA, USA). Evaluation of PET-PCR amplification efficiency and reproducibility was performed using a 10-fold dilution of a *P. falciparum* control strain (3D7), with parasite densities of 2,000 parasites/ $\mu$ l to 2 parasites/ $\mu$ l. The amplification efficiencies of the *PfPM2* and the *P. falciparum*  $\beta$ -tubulin gene PET-primers were 97% and 100%, respectively (Fig. 1A and B). The *PfPM2* copy number was determined by the  $2^{-\Delta\Delta C_T}$  method ( $\Delta C_T = C_T$  *PfPM2* -  $C_T$  *P. falciparum*  $\beta$ -tubulin gene;  $C_T$ , threshold cycle) using the 3D7 *P. falciparum* strain, known to have a single copy of the *PfMD2* gene, as a calibrator and two additional controls (control 2 [Ctrl-2] and Ctrl-3 obtained from Cambodia with one copy and three copies, respectively). To validate the accuracy of the PET-PCR for copy number variation determination, six additional clinical samples, all obtained from Cambodia, with known *PfMD2* copy numbers were tested in a blinded fashion using both the novel PET-PCR and the previously reported singleplex TaqMan probe-based assay. These specimens were kindly provided by R. M. Fairhurst's (samples MB-PPQ-001 to MB-PPQ-004) and D. Fidock's (samples MB-PPQ-005 and MB-PPQ-006) laboratories and were previously evaluated for *PfMD2* copy numbers using probe-based real-time PCR assays and/or whole-genome sequencing. The PET-PCR multiplex *PfPM2* copy number results had 100% agreement with the previously published results of the singleplex TaqMan probe-based assay (16) (Table 2).

Simple molecular tools are valuable for conducting molecular surveillance of drug



**FIG 1** Amplification efficiencies of the novel PET-PCR primers. The amplification efficiency (Eff) of the *PfPM2* primers were 97% (A), and that of the *P. falciparum*  $\beta$ -tubulin gene primers was 100% (B).

**TABLE 2** Comparison between PET-PCR and TaqMan probe-based real-time PCR assay<sup>a</sup>

Sample ID <sup>b</sup>	Observed no. of <i>PfPM2</i> copies	
	PET-PCR	TaqMan-based real-time PCR
Ctrl-1 (strain 3D7)	1	1
Ctrl-2	1	1
Ctrl-3	3	3
MB-PPQ-001	1	1
MB-PPQ-002	1	1
MB-PPQ-003	1	1
MB-PPQ-004	3	3
MB-PPQ-005	2	2
MB-PPQ-006	3	3

<sup>a</sup>The PET-PCR multiplex *PfPM2* copy number results had 100% agreement with previously published singleplex real-time PCR assay results (16). Ctrl, control samples; MB-PPQ-001 to -006, clinical samples that were kindly provided by R. M. Fairhurst and D. Fidock.

<sup>b</sup>ID, identification number.

resistance markers. The PET-PCR is a molecular diagnostic assay with performance characteristics that are similar to those of commonly used real-time PCR methods, but the PET-PCR is less expensive, easy to use, and can be used for large-scale surveillance studies, even in developing country settings (17). The novel multiplex PET-PCR assay for *PfPM2* copy number determination has performance characteristics similar to those of a singleplex TaqMan probe-based assay but without the need for running two independent PCRs. The novel assay provides a useful cost-effective alternative for the evaluation of the *PfPM2* copy number. As monitoring for piperazine resistance is gaining momentum and urgency, it is hoped that this new method will help enhance molecular surveillance in a timely manner even in reference laboratories in countries endemic for the disease. In addition, the PET-PCR format described here provides an alternative real-time PCR format that can be utilized for the determination of any gene amplification of interest.

#### ACKNOWLEDGMENTS

We thank the Malaria Branch, CDC, for supporting this project, and David Fidock, Leila Ross, Rick M. Fairhurst, and Didier Menard for providing the clinical samples and controls used in this study. Also, we give a special thank you to Ira Goldman for reviewing the article.

We acknowledge funding support for this study from the CDC Antimicrobial Resistance Working Group.

The use of trade names and names of commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. The findings and conclusions in this presentation are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention.

#### REFERENCES

- WHO. 2016. World malaria report. World Health Organization, Geneva, Switzerland.
- Bousema T, Drakeley C. 2011. Epidemiology and infectivity of *Plasmodium falciparum* and *Plasmodium vivax* gametocytes in relation to malaria control and elimination. *Clin Microbiol Rev* 24:377–410. <https://doi.org/10.1128/CMR.00051-10>.
- Reference deleted.
- Ashley EA, White NJ. 2005. Artemisinin-based combinations. *Curr Opin Infect Dis* 18:531–536. <https://doi.org/10.1097/01.qco.0000186848.46417.6c>.
- World Health Organization. 2006. Guidelines for the treatment of malaria. World Health Organization, Geneva, Switzerland.
- Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ, Wellem TE, Ringwald P, Newman RD, Plowe CV. 2011. The threat of artemisinin-resistant malaria. *N Engl J Med* 365:1073–1075. <https://doi.org/10.1056/NEJMp1108322>.
- Fairhurst RM. 2015. Understanding artemisinin-resistant malaria: what a difference a year makes. *Curr Opin Infect Dis* 28:417–425. <https://doi.org/10.1097/QCO.0000000000000199>.
- Packard RM. 2014. The origins of antimalarial-drug resistance. *N Engl J Med* 371:397–399. <https://doi.org/10.1056/NEJMp1403340>.
- Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, Kawamoto F, Miller RS, Meshnick SR. 2003. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in *pfmdr1*. *Antimicrob Agents Chemother* 47:2418–2423. <https://doi.org/10.1128/AAC.47.8.2418-2423.2003>.
- Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, Nosten F, Krishna S. 1999. The *pfmdr1* gene is associated with a

- multidrug-resistant phenotype in *Plasmodium falciparum* from the western border of Thailand. *Antimicrob Agents Chemother* 43:2943–2949.
11. Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, Almagro-Garcia J, Neal AT, Sreng S, Suon S, Drury E, Jyothi D, Stalker J, Kwiatkowski DP, Fairhurst RM. 2017. Genetic markers associated with dihydroartemisinin-piperazine failure in *Plasmodium falciparum* malaria in Cambodia: a genotype-phenotype association study. *Lancet Infect Dis* 17:164–173. [https://doi.org/10.1016/S1473-3099\(16\)30409-1](https://doi.org/10.1016/S1473-3099(16)30409-1).
  12. Ariev F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature* 505:50–55. <https://doi.org/10.1038/nature12876>.
  13. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroeth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runchaoren R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshetu AK, Mishra N, Valecha N, Phyto AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, et al. 2014. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 371:411–164 423. <https://doi.org/10.1056/NEJMoa1314981>.
  14. Parobek CM, Parr JB, Brazeau NF, Lon C, Chaorattanakawee S, Gosi P, Barnett EJ, Norris LD, Meshnick SR, Spring MD, Lanteri CA, Bailey JA, Saunders DL, Lin JT, Juliano JJ. 2017. Partner-drug resistance and population substructuring of artemisinin-resistant *Plasmodium falciparum* in Cambodia. *Genome Biol Evol* 9:1673–1686. <https://doi.org/10.1093/gbe/evx126>.
  15. Dondorp AM. 2017. New genetic marker for piperazine resistance in *Plasmodium falciparum*. *Lancet Infect Dis* 17:119–121. [https://doi.org/10.1016/S1473-3099\(16\)30414-5](https://doi.org/10.1016/S1473-3099(16)30414-5).
  16. Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, Chy S, Kim S, Ke S, Kloeng N, Eam R, Khean C, Ken M, Loch K, Bouillon A, Domergue A, Ma L, Bouchier C, Leang R, Huy R, Nuel G, Barale JC, Legrand E, Ringwald P, Fidock DA, Mercereau-Puijalon O, Ariev F, Menard D. 2017. A surrogate marker of piperazine-resistant *Plasmodium falciparum* malaria: a phenotype-genotype association study. *Lancet Infect Dis* 17:174–183. [https://doi.org/10.1016/S1473-3099\(16\)30415-7](https://doi.org/10.1016/S1473-3099(16)30415-7).
  17. Lucchi NW, Narayanan J, Karell MA, Xayavong M, Kariuki S, DaSilva AJ, Hill V, Udhayakumar V. 2013. Molecular diagnosis of malaria by photo-induced electron transfer fluorogenic primers: PET-PCR. *PLoS One* 8:e56677. <https://doi.org/10.1371/journal.pone.0056677>.
  18. Talundzic E, Ndiaye YD, Deme AB, Olsen C, Patel DS, Biliya S, Daniels R, Vannberg FO, Volkman SK, Udhayakumar V, Ndiaye D. 2017. Molecular epidemiology of *Plasmodium falciparum* *kelch13* mutations in Senegal determined by using targeted amplicon deep sequencing. *Antimicrob Agents Chemother* 61:e02116-16. <https://doi.org/10.1128/AAC.02116-16>.